STAT

3 issues to watch in global health in 2018

What global health stories will we tell about 2018? The crystal ball is cloudy, but the haze parted long enough for us to discern a few things.

As 2018 begins, STAT reporters are taking a look at the stories they’re most eager to track this year. Find all our “three to watch” series here

Some years there’s a single global health story that dominates the headlines, like Ebola in 2014 or Zika in 2016. But 2017 wasn’t one of those years.

There were a number of big stories, and big challenges. A devastating in Yemen. An alarming epidemic of in Madagascar. The spread of in Syria, which paralyzed 74 children who were already struggling to survive the country’s relentless and bloody civil war. On a happier note, the World Health Organization got a, Tedros Adhanom Ghebreyesus of Ethiopia.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks